
Daily Derm Times: April 2, 2025
Key Takeaways
- Unrealistic expectations for pregnancy-related skin conditions arise from misinformation, particularly regarding hyperpigmentation.
- Guselkumab shows high efficacy in bio-naïve psoriasis patients without comorbidities.
Catch up on dermatology news, highlights, and insights from the past 24 hours.
To stay up-to-date with the latest dermatology news, sign up to receive our
New Data on the Perception of Pregnancy-Related Skin Changes
Misinformation from outside sources creates unrealistic expectations for pregnancy and postpartum skin conditions like hyperpigmentation.
Guselkumab Shows Strong Response in Long-Term Subtype Psoriasis Study
Bio-naïve patients and those without comorbidities had the highest treatment success rates with guselkumab.
New Research Highlights Underreported Risks of Deprescribing
Researchers call for standardized methods to assess and report ADWEs in deprescribing trials to ensure reliable data and clinical confidence.
Quality of Life Improvements after Psoriasis Cal/BD Aerosol Foam Treatment
Positive changes in DLQI scores were observed after 4 weeks of therapy as well as the 6-month follow-up.
Exploring the 2025 Revolutionizing Atopic Dermatitis (RAD) Annual Meeting Agenda
Get a glimpse of the cutting-edge atopic dermatitis research, breakthroughs, and insights to be presented at the 7th RAD Annual Meeting, June 6-7, 2025.
Hand Eczema Prevalence and Patterns in East Greenland Similar to Nordic and European Trends
Hand eczema affects 22.4% of adults in East Greenland, with prevalence, severity, and risk factors mirroring trends other populations.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


















